Ex-Bolar CEO Shulman
Executive Summary
Sentencing for Shulman's FD&C Act violations has been postponed from Sept. 25 to Oct. 27 to permit Justice Department to file charges for antitrust violations. The sentencing is scheduled to begin at 9:30 a.m. in Baltimore federal court. Shulman pled guilty last November to five counts of conspiracy, wire fraud, false statements to FDA and obstruction of an agency investigation. He could receive more than five years in jail and/or fines of $1.25 mil.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth